Brief: Newlink Genetics Announces Exclusive License Agreement With Ellipses Pharma
23/12/2019 21:15
Dec 23 (Reuters) - NewLink Genetics Corp NLNK.O :
* NEWLINK GENETICS ANNOUNCES EXCLUSIVE WORLDWIDE LICENSE
AGREEMENT
WITH ELLIPSES PHARMA FOR DEVELOPMENT OF AND RIGHTS TO
COMMERCIALIZATION OF NLG207
* NEWLINK GENETICS CORP - UNDER TERMS OF AGREEMENT, ELLIPSES
PURCHASED NEWLINK'S INVENTORY OF NLG207 RELATED MATERIALS
* NEWLINK GENETICS CORP - NEWLINK WILL HAVE POTENTIAL TO
RECEIVE
FUTURE ROYALTY PAYMENTS OR A SHARE OF ANY FUTURE ECONOMICS
RELATED TO NLG207
* NEWLINK GENETICS - ELLIPSES GAINED RIGHTS TO DEVELOP,
COMMERCIALIZE CRLX-301, A NANOPARTICLE FORMULATION OF DOCETAXEL
THAT HAS COMPLETED PHASE 1A STUDY
Source text for Eikon: ID:nGNXbyBs2K
Further company coverage: NLNK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)